• Explore /
  • Poster
  • / Outcomes in patients with advanced non-small cell lung cancer (aNSCLC) and high PD-L1 expression treated with immune checkpoint inhibitor monotherapy: An FDA-pooled analysis.

Outcomes in patients with advanced non-small cell lung cancer (aNSCLC) and high PD-L1 expression treated with immune checkpoint inhibitor monotherapy: An FDA-pooled analysis.

Abstract Poster

Authors

null

Sujay Yogesh Shah

Food & Drug Administration, Silver Spring, MD

Sujay Yogesh Shah , Jonathon Joseph Vallejo , Yutao Gong , Thomas D. Brown , Chenan Zhang , Jonathan Hirsch , Shenghui Tang , Gideon Michael Blumenthal , Harpreet Singh , Paul Gustav Kluetz , Marc Robert Theoret , Julia A. Beaver , Richard Pazdur

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9606)

DOI

10.1200/JCO.2020.38.15_suppl.9606

Abstract #

9606

Poster Bd #

372

Abstract Disclosures

Similar Posters

First Author: Mario Machado Lopes

First Author: Claudia Proto

Poster

2024 ASCO Annual Meeting

<span>PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.</span>

PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.

First Author: Lingzhi Hong

First Author: Xiaoting Ma